as 05-20-2024 1:33pm EST
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.
Founded: | 2011 | Country: | United States |
Employees: | N/A | City: | PALO ALTO |
Market Cap: | 97.5M | IPO Year: | N/A |
Target Price: | $6.00 | AVG Volume (30 days): | 1.0M |
Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -1.31 | EPS Growth: | N/A |
52 Week Low/High: | $0.73 - $8.37 | Next Earning Date: | 05-13-2024 |
Revenue: | $47,045,000 | Revenue Growth: | 12.54% |
Revenue Growth (this year): | 89.87% | Revenue Growth (next year): | 1.38% |
SCLX Breaking Stock News: Dive into SCLX Ticker-Specific Updates for Smart Investing
MT Newswires
6 days ago
MT Newswires
6 days ago
GlobeNewswire
6 days ago
Zacks Small Cap Research
6 days ago
GlobeNewswire
7 days ago
GlobeNewswire
25 days ago
GlobeNewswire
a month ago
GlobeNewswire
a month ago